[Hypothyroidism in patients with heart disease]

Area of Science:

• Cardiology
• Endocrinology
• Internal Medicine

Background:

• Hypothyroidism is prevalent in heart disease patients, acting as a risk factor for atherosclerosis and ischemic heart disease.
• It directly impairs left and right ventricular function, leading to hypothyroidism-induced cardiomyopathy.
• Thyroid peroxidase antibodies are often implicated.

Purpose of the Study:

• To evaluate the management of hypothyroidism, particularly subclinical hypothyroidism, in patients with heart disease.
• To determine the age-dependent efficacy and risks of levothyroxine replacement therapy.
• To guide treatment decisions based on patient age and cardiovascular risk profile.

Main Methods:

• Review of current clinical practices and literature regarding hypothyroidism management in cardiac patients.
• Analysis of the benefits and risks of levothyroxine therapy in different age groups.
• Assessment of thyroid stimulating hormone (TSH) level targets in heart disease patients.

Main Results:

• Manifest hypothyroidism requires levothyroxine replacement, initiated at low doses and titrated carefully in cardiac patients.
• Treatment of subclinical hypothyroidism in heart disease patients yields controversial benefits, highly dependent on age.
• For younger patients (<65 years), therapy is generally effective; for older patients (>80 years), risks often exceed benefits.

Conclusions:

• Levothyroxine therapy for manifest hypothyroidism is standard in cardiac patients, requiring cautious dose escalation.
• Subclinical hypothyroidism treatment in heart disease is most effective in younger individuals.
• In elderly patients (>80 years), conservative management of subclinical hypothyroidism is preferred due to elevated risks.